TCRR

TCR2 Therapeutics (TCRR)

TCR2 Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:TCRR

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2023/06/12	20 : 01	Edgar (US Regulatory)	Termination of Registration of a Class of Security Under Section 12(g) (15-12g)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/06	19 : 03	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/06	19 : 03	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/06	19 : 02	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/06	05 : 38	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/06	05 : 37	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/06	05 : 37	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/06	05 : 36	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/02	05 : 46	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/02	05 : 44	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/02	05 : 42	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/02	05 : 41	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/02	05 : 40	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/02	05 : 39	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/02	05 : 32	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/02	05 : 30	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/02	05 : 25	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/02	05 : 24	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/02	05 : 19	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/02	05 : 16	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/02	05 : 11	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/06/01	22 : 35	Edgar (US Regulatory)	Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/05/31	05 : 22	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/05/31	05 : 17	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/05/25	05 : 57	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/05/25	05 : 53	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/05/25	05 : 53	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/05/25	05 : 45	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/05/25	05 : 45	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
2023/05/22	20 : 34	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:TCRR	TCR2 Therapeutics Inc